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Introduction
Corticosteroids (CSs)' have assumed an important role in the treatment of a wide range of diseases, including those with inflammatory or immune-mediated components (1, 2) . Many of these diseases are mediated in part by humoral mechanisms such as autoantibody production and/or immune complex deposition. Despite the clinical importance of CS, the precise mechanisms of CS-induced immunoregulation of immunoglobulin (Ig) production have not been clearly defined. This has been due in part to the fact that B cell function is usually measured as Ig production, which is the final terminal expres-sion of the B cell activation pathway. Because little was known until recently about the various phases of the B cell cycle, virtually no information has been available concerning the direct effects of CSs on human B cells at different states of activation. Furthermore, most measurable B cell functions are regulated by one or more types of accessory cells (3) . Therefore, the observed effects of CSs on B cell function may well be due to the effects on the immunoregulatory accessory cells.
Investigation in this and other laboratories has resulted in delineation of the sequential events in the human B cell activation cascade (4) (5) (6) (7) (8) . By using this model system, it has been shown that resting B cells can be activated by a number of initial signals. After activation, the B cells are then capable of responding directly and sequentially to a number of T cellderived growth and differentiation factors such as B cell growth factor (BCGF) and B cell differentiation factor. In the present study, we have utilized this model system of the B cell cycle to demonstrate the selective effects of in vitro CSs on various phases of B cell activation, proliferation, and differentiation.
Methods
Subjects. 14 healthy men and women aged 20-34 yr were studied.
Drugs. Hydrocortisone sodium succinate (Upjohn Co., Kalamazoo, MI) was reconstituted in RPMI 1640 before being used in the in vitro studies.
Standard cell separations. Heparinized blood was immediately diluted 1:1 (vol/vol) with iced phosphate-buffered saline (PBS) pH 7.4, and unfractionated (UF) mononuclear cell suspensions were obtained by Ficoll-Hypaque (Ficoll, Pharmacia Fine Chemicals, Piscataway, NJ; Hypaque, Winthrop Laboratories, New York) density centrifugation (9) . The UF mononuclear cells were initially depleted of T cells by rosetting with 2-aminoethylisothiouronium bromide-treated sheep erythrocytes (AET-SRBC) followed by separation by Ficoll-Hypaque density centrifugation (10) . Further T cell depletion was performed either by repeating the AET-SRBC separation or by incubating the AET-SRBC rosette-negative cells with Leu-l (anti-pan T lymphocyte) mouse monoclonal antibody ( In some experiments, the TCD fractions were further monocyte depleted as described previously (1 1 Cell viability. Cell viability was determined at various times during the culture period by trypan-blue dye exclusion. Determination of Ig-secreting cells. The ability of B lymphocytes to secrete Ig was measured in an indirect plaque-forming cell (PFC) assay using target SRBC coated with staphylococcal protein A and a developing rabbit antihuman polyvalent (anti-IgG, + IgA, +IgM) antibody (Cappel Laboratories) as previously described in detail (16) . Two protocols to stimulate TCD cell fractions to develop into Igsecreting cells were employed. In the first assay, 5 X 105 TCD cells were cultured in 10 X 75-mm plastic tubes in the presence of 10% FCS, RPMI 1640 with 2 mM glutamine, gentamicin 1% with SAC 1: 50,000 (vol/vol) final concentration, and a final total volume of 1.0 ml as previously described (5). On the second day after the culture was set up, 0.5 ml of the culture supernatant was removed and replaced with 0.5 ml of MLR-SN. After 6 d, a PFC assay was performed on the cultured cells in order to determine the number of Ig-secreting cells. In the second assay, 5 X 105 TCD cells were cultured in 10% FCS, RPMI 1640 with 2 mM glutamine, 1% gentamicin, and 0.5 ml mitogen-stimulated crude T cell-derived supernatant added at the beginning of the culture period to a total volume of I ml in a 10 X 75-mm plastic tube (17) . These cultures were also harvested after 6 d in culture to determine the number of Ig-secreting cells.
B cell co-stimulatory assay. A human B cell co-stimulatory assay described by Muraguchi et al. (8) was used with minor modifications. The assay is designed to determine the synergistic effects of BCGF on the human B cell proliferative response after in vitro activation with SAC or anti-pg. Briefly, 1 X 105 B cells were cultured in 0.2 ml of 10% FCS, RPMI 1640 containing 2 mM glutamine with (a) SAC 1:50,000 final dilution or 20 pg/ml protein anti-p and (b) 50% by volume BCGF. Cultures were processed as previously noted. The degree of synergy in co-stimulatory cultures was determined by calculating the difference in counts between cultures with SAC or anti-pu alone and BCGF alone compared with cultures with both.
Results
Effect of in vitro hydrocortisone on B cell proliferation. The effects of in vitro hydrocortisone sodium succinate on proliferative responses of B cells plus monocyte cell fractions (TCD cell populations) are shown in Fig. 1 . There is a dosedependent suppression of both ( Fig. 1 A) SAC-stimulated and (Fig. 1 B) high-dose anti-,-stimulated B cell proliferative responses in this population of cells. At 10-6 M hydrocortisone, which is an in vivo obtainable pharmacologic dose (3), the SAC-stimulated response is 35% and the anti-,u-stimulated Fig. 2 . Although the absolute magnitude of the proliferative responses increases with increasing concentrations of SAC, the degree of CS-induced suppression is similar for the three concentrations evaluated. Similarly, dose-response curves up to 200 and 100 gg/ml of anti-I did not demonstrate a shift in the CS-induced suppression of the B cell proliferative response (Fig. 2 B) . Kinetic studies in two separate experiments from day 2 to day 6 for both SAC-induced and anti-jL-stimulated proliferation did not demonstrate a CS-induced shift of the peak response (data not shown). Thus, CS-induced suppression of SAC-and anti-si-stimulated B cell blastogenesis is not the result of altered cell viability, a change in the dose response curve, or a shift in the kinetic curve for peak proliferative responses.
Effect of in vitro hydrocortisone added at various times on B cell proliferation. The time dependence of the in vitro CSinduced suppression of B cell proliferation is shown in Fig. 3 . CS added after the initiation of culture and up to 1 d later significantly suppressed B cell proliferative responses. By the second day of culture, the addition of hydrocortisone had minimal effects on B cell proliferation.
Effect of monocytes on CS-induced suppression of B cell proliferation. To evaluate the role of accessory cell function in CS-induced modulation of B cell proliferative responses, studies were performed on cell fractions which had been rigorously depleted of monocytes (Fig. 4) . In these monocyte-depleted fractions, CS-induced suppression of anti-iu-stimulated B cell proliferation was unaltered (Fig. 4 B) . In contrast, rigorous monocyte depletion markedly altered the CS-induced suppression of SAC-induced B cell blastogenesis (Fig. 4 A) Functional characterization of small and large peripheral blood B cells separated by counterfilow centrifugation-elutriation.
The functional characteristics of small and large peripheral blood B cells are summarized in Fig. 5 . In the absence of in vitro stimulation, small B cells do not proliferate in response to monoclonal BCGF or mitogen-stimulated crude T cellderived supernatants (Fig. 5 A) . In contrast, large B cells, which presumably hav'e been activated in vivo, respond directly to monoclonal BCGF and crude T cell-derived soluble factors. In addition, the majority of peripheral blood B cells which will differentiate into PFC in the presence of T cell supernatants are found in the large cell population (Fig. 5 B) (8) . The effect of in vitro CS on the co-stimulatory response is shown in Fig. 6 . There is less suppression of the co-stimulatory response compared with the CS-induced suppression of SAC The effect of in vitro hydrocortisone on the PFC responses after stimulation with SAC plus MLR-SN or after culture with mitogen-stimulated crude T cell-derived supernatants alone was measured (Fig. 8) 
Discudsion
The present study demonstrates the graded effect of in vitro CSs on B cell activation, proliferation, and differentiation. (20) (21) (22) . Proliferative responses to PWM measured on day 5 and felt to represent B cell proliferation are reported to be relatively refractory to the suppressive effects of in vitro CSs (20) . Similarly, PWMstimulated proliferation in B cell-enriched populations is relatively resistant to CS-induced suppression (21) . Moreover, CSinduced -suppression of PWM'blastogenesis can be overcome by increasing the dose of the mitogen (22 human B cell proliferation in direct response to anti-js and SAC can be readily demonstrated despite extensive accessory cell depletion (8, 24) and appear to act through the surface Ig receptor (25, 26) . There is a dichotomy in the effect of rigorous monocyte depletion qn CS-induced suppression of SAC-induced and anti-,g-stimplated B cell proliferation. Rigorous monocyte depletion of anti-g-stimulated B cells has no effect on the CSinduced supression of proliferation. This observation suggests that CS may directly affect the B cell rather than modulate the response through an accessory cell such as monocytes for high-dose anti-,g-stimulated proliferation. In contrast, CS-induced suppression of SAC-stimulated B cell proliferation is dependent upon the presence of monocytes in the culture. Rigorous monocyte deletion greatly lessens CS-induced suppression of SAC-induced B cell proliferation. The importance of CS-induced effects on monocyte function in the modulation of lymphocyte-mediated aspects of the immune response has been emphasized (3). CS-induced modulation of lymphokine production is instrumental in suppressing T cell functional capabilities (27, 28) . Studies done in the mouse suggest that CS modulation of macrophage interleukin-I production with subsequent suppression of interleukin-2 production is an important mechanism in CS-induced suppression of T cell proliferative responses (29, 30) . In addition, CS-induced modulation of release of monocyte-soluble factors other than interleukin-I is recognized (31) In contrast to the CS-induced suppression of B cell activation and proliferation, B cell differentiation to an Ig-produced state is either unaltered or enhanced by the presence of in vitro CSs depending on the experimental system employed. The effect of in vitro CSs on Ig production is variable depending on a number of experimental parameters (3). For example, in certain systems, in vitro Ig production is enhanced by the presence of CS in culture (34) (35) (36) (37) . The CS-induced potentiation of the SAC-stimulated PFC responses is in agreement with these previously noted observations. However, the PFC response after stimulation of larger in vivo-activated B cells with soluble T cell factors was unaltered by in vitro CS. CSs appear to be able to potentiate Ig production in systems that require the presence of an in vitro activation signal. In the system where the B cells have been activated in vivo and only seem to require the presence of a soluble T cell factor to differentiate, in vitro CSs did not appear to suppress or enhance the response. Taken together, these observations suggest that CSs modulate the B cell differentiation responses earlier in the B cell activation sequence. Cells further along the B cell differentiation cycle are relatively refractory to the immunomodulatory effect of in vitro CSs.
It is obvious from this report that immunomodulation of B cell responses by in vitro CSs is quite complex. Different phases of the B cell cycle have a graded sensitivity to the immunomodulatory effects of in vitro CSs. The ability to evaluate the discrete events in the B cell activation-proliferation-differentiation cycle provides insights intQ the complex and multifaceted immunomodulatory effects of CS. Hopefully, these studies will provide insights towards our understanding not only the effects of CS on B cell function but also the impact of CS treatment on diseases characterized by abnormalities of B cell reactivity.
